Page 80 - Aet News Today

San Francisco-based Plenful emerged from stealth on Tuesday. The startup sells a workflow tool that automates manual and administrative workflows for pharmacy technicians. In addition to its launch out of stealth mode, the company also announced that it has closed a $9 million funding round led by Bessemer Venture Partners and signed contracts with more than 20 customers.

Policymakers must work to increase access to the Medicare Kidney Disease Education Benefit and expand the Medicare annual wellness benefit to include kidney disease screening. These reforms will catch disease at earlier stages and equip patients to better recognize their risk.

Hospitals’ operating margins are still in a worse place than they were before the pandemic, but 2023 is shaping up to be a much more stable year for hospital finance than 2022, according to a new report from Kaufman Hall. Because this year hasn't had any large Covid-19 surges, hospitals have seen less variability in patient volumes. This has helped them allocate their resources more efficiently and decrease their reliance on expensive contract labor.

While it's easy to be consumed by the latest technology and the potential influence it could have, it's important to remember the ultimate role these platforms should play when it comes to improved patient outcomes. 

A new J.D. Power report found that CVS ranks highest for telehealth satisfaction among direct-to-consumer companies, while UnitedHealthcare ranks highest among payers.

Novartis’s iptacopan met the first of two main goals in its pivotal study in immunoglobulin A nephropathy, and the pharma giant plans to seek accelerated FDA approval next year. The drug could challenge two available therapies for the rare kidney disorder.

Healthcare-focused market research firm Trilliant Health published a report detailing the 10 most significant economic trends affecting U.S. healthcare stakeholders in 2023. Some of the main ideas covered in the report included Americans’ worsening physical and mental health, the industry’s shift away from traditional care pathways, and the way patients' decision making is becoming increasingly driven by consumerism.

Acquiring Point Biopharma gives Eli Lilly a pipeline of radiopharmaceuticals, including one for prostate cancer that could rival Novartis’s Pluvicto. The deal comes ahead of an expected Phase 3 data readout for that Point therapeutic candidate.

7wireVentures launched its largest fund to date on Tuesday — the closing of the $217 million digital health fund brings the Chicago-based firm’s assets under management to more than $500 million. Two-thirds of the new fund's capital will be allocated to 7wireVentures’ existing portfolio companies for follow-up investments, and the remaining third will go toward Series B and Series C funding round for companies in which the firm hasn’t yet invested.

Solera Health recently launched HALO, a platform that allows payers and employers to manage both Solera point solution partners and non-Solera point solutions in one place.